Biomarkers and Prediction of Tigecycline Induced Coagulation Dysfunction

Nanjing University

Status: Not yet enrolling

Conditions: Blood Coagulation Disorder

Study type: Observational

Funder types: Other

Identifiers

NCT05698160

2022-LCYJ-PY-14

Details and patient eligibility

About

This study is to screen out the biomarkers and establish the model to predict coagulation dysfunction induced tigecycline

Full description

The critically ill patients treated with tigecycline in in tensive care unit will be recruited and divided into tigecycline-induced coagulation dysfunction group and non-coagulation dysfunction group. The multi-omics will be used to screen out biomarkers for early prediction of coagulation dysfunction caused by tigecycline. Afterwards, machine learning methods will be adopted to establish the the early prediction model of tigecycline-induced coagulation dysfunction.

Enrollment: 200 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Inpatients receiving tigecycline treatment in the Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
• Intravenous tigecycline ≥ 3 days
• Monitoring the plasma concentration of tigecycline

Exclusion criteria

• Missing clinical data

Trial design

200 participants in 2 patient groups

coagulation dysfunction group

Description:

The critically ill patients in intensive care unit showed coagulation dysfunction after treated with tigecycline.

non-coagulation dysfunction group

Description:

The critically ill patients in intensive care unit showed normal coagulation function after treated with tigecycline.